You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Dow
AstraZeneca
Medtronic
McKinsey
Johnson and Johnson

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Brivanib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Brivanib?

Brivanib is an investigational drug.

There have been 25 clinical trials for Brivanib. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Colorectal Neoplasms. The leading clinical trial sponsors are Bristol-Myers Squibb, National Cancer Institute (NCI), and Zai Lab (Shanghai) Co., Ltd.

Recent Clinical Trials for Brivanib
TitleSponsorPhase
Niraparib Combined With Brivanib in Patients With Cervical CancerChongqing University Cancer HospitalPhase 2
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer PatientsZai Lab (Shanghai) Co., Ltd.Phase 1/Phase 2
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerHunan Cancer HospitalPhase 1

See all Brivanib clinical trials

Clinical Trial Summary for Brivanib

Top disease conditions for Brivanib
Top clinical trial sponsors for Brivanib

See all Brivanib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
McKinsey
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.